When treatment helps, but you're still making plans around a possible flare, there's more to discuss than the number of hives ...

A little over a year after landing its flagship approval in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is expanding ...

Novartis AG NVS on Wednesday secured the U.S. Food and Drug Administration (FDA) approval for Rhapsido (remibrutinib) to ...

The recent FDA approval of remibrutinib (Rhapsido) for symptomatic dermographism (SD) gives clinicians an on-label option for a condition long managed with off-label therapies, Raj Chovatiya, MD, PhD, ...

In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with ...

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include ​a second indication, symptomatic ...

The FDA has approved an expanded indication for remibrutinib as the first treatment for adults with symptomatic dermographism ...

When red bumps suddenly spread all over your body, you might feel anxious, wondering, "Is it an allergy?" or "Should I go to ...

The FDA has approved Rhapsido (remibrutinib) for adults with symptomatic dermographism who remain symptomatic despite use of ...

I developed hives at the beginning of July. The symptoms dragged on, and I was subsequently diagnosed with "chronic urticaria."At first, it was somewhat controlled by a mild antihistamine, but the ...

The approval will allow the drugmaker to expand the use of its Bruton tyrosine kinase inhibitor, already approved for chronic ...